Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Feb 12;5(3):FSO375.
doi: 10.4155/fsoa-2018-0122. eCollection 2019 Mar.

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race

Ricardo García-Muñoz  1   1 , Judit Anton-Remirez  2   2 , María Josefa Nájera  1   1 , Elena Gutierrez-Gamarra  3   3 , Raisa Peralta  1   1 , Jesús Feliu  1   1
Affiliations
Editorial

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race

Ricardo García-Muñoz et al. Future Sci OA. .
No abstract available

Keywords: ADCC; NK-cell; follicular lymphoma; obinutuzumab.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

References

    1. Mössner E, Brünker P, Moser P, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new Type II anti-CD20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood. 2010;115(22):4393–4402. - PMC - PubMed
    1. García-Muñoz R, López-Díaz-de-Cerio A, Feliu J, et al. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity. Immunol. Res. 2016;64(2):548–557. - PubMed
    1. Sehn LH, Goy A, Offner FC, et al. Randomized Phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J. Clin. Oncol. 2015;33:3467–3474. - PMC - PubMed
    1. Marcus R, Devies A, Ando K, et al. Obinutuzumab for the first-line treatment of Follicular lymphoma. N. Eng. J. Med. 2017;377(14):1331–1344. - PubMed
    1. Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the randomized Phase III GALLIUM study: influence of chemotherapy regimen on efficacy and safety. J. Clin. Oncol. 2018;36:2395–2404. - PubMed

Publication types

LinkOut - more resources